18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: Systematic review of the literature

Annals of Surgery

Volumn 250, Issue 2, 2009, Pages 247-254

  Rebollo Aguirre, Ángel C ^a   Ramos Font, Carlos ^a   Villegas Portero, Román ^b   Cook, Gary J R ^c   Llamas Elvira, José M ^a   Tabares, Antonio Romero ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b Andalusian Agency for Health Technology Assessment Spain   (Spain)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Esophageal neoplasm; Fluorodeoxyglucose F18; Neoadjuvant therapy; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DATA EXTRACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ESOPHAGUS CANCER; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADJUVANT THERAPY; ESOPHAGUS TUMOR; PATHOLOGY; REVIEW; SCINTISCANNING; TREATMENT OUTCOME;

ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 68949085546     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b0c3a6     Document Type: Article

References (39)

1. CANCERMondial. Globocan 2002. Available at: http://www.dep.iarc.fr/.
2. Hulscher JB, Tijssen JG, Obertop H, et al. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. Accessed October 29, 2008. 2001;72:306-313.
3. Allum WH, Powell DJ, McConkey CC, et al. Gastric cancer: A 25-year review. Br J Surg. 1989;76:535-540.
4. Rudiger Siewert J, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/ topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232: 353-361.
5. Schrump DS, Altorki NK, Forastiere AA. Cancer of the esophagus. In: De Vita VT, Hellman S, Rosemberg SA, eds. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1051-1091.
6. Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007;83:1257-1264.
7. Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastresophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003;7:754-761.
8. Schwaiger M, Peschel C. Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):S1-S5.
9. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in esophageal carcinoma: Role of surgery and other modalities. Lancet Oncol. 2007;8:545-553. (Pubitemid 46813024)
10. Gwyter SJ. Current standards for response evaluation by imaging techniques. Eur J Nucl Med Mol Imaging. 2006;33:S11-S15.
11. Juweid ME, Cheson BD. Positronemission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507.
12. Dehdashti F, Siegel B. Neoplasm of the esophagus and the stomach. Semin Nucl Med. 2004;34:198-208.
13. Sloof GW. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET. Best Pract Res Clin Gastroenterol. 2006;20:941-957.
14. Flamen P, Lerut T, Haustermans K, et al. Positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging. 2004;48:96-108.
15. Kostakoglu L, Goldsmith S. PET assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004;45:56-68.
16. Erasmus JJ, Munden RF. The role of integrated computed tomography positronemission tomography in esophageal cancer: Staging and assessment of therapeutic response. Semin Radiat Oncol. 2006;17:29-37.
17. Bidwell S, Jensen MF. Using a search protocol to identify sources of information: the COSI model. In: National Information Center on Health Services Research and Health Care Technology. Etext on Health Technology Assessment (HTA) Information Resources Internet . Bethesda, MD: National Library of Medicine; 2003:(Chap 3. Available at):http://www.nlm.nih.gov/ archive//2060905/nichsr/ ehta/ehta.html. Accessed October 29, 2008.
18. Whiting P, Rutjes AWS, Reitsma JB, et al. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25-37.
19. Whiting PF, Westwood ME, Rutjes AWS, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9-16.
20. Schelbert RS, Hoh CK, Royal HD, et al. Society of Nuclear Medicine procedure guideline for tumor imaging using F-18 FDG, version 2.0 SNM Web site Available at: http://interactive.snm.org/index.cfm-PageID5772&RPID5969. Accessed 1999.
21. Bombardieri E, Aktolun C, Baum RP, et al. European Association of Nuclear Medicine FDG-PET procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP115-BP124.
22. Delbeke D, Coleman RE, Guiberteau MJ, et al. Society of Nuclear Medicine procedure guideline for tumor imaging with 18F-FDG PET/CT. J Nucl Med. 2006;47:885-895.
23. Grupo PET de la SEMN. Whole body positron emission tomography (PET) with (18F)-fluorodeoxyglucose. Rev Esp Med Nucl. 2002;21:128-130.
24. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;12:31.
25. Westerterp M, Van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology. 2005;236:841-851.
26. Brink I, Hentschel M, Bley TA, et al. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol. 2004;30:544-550.
27. Cerfolio RJ, Bryant AS, Ohja B, et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129:1232-1241.
28. Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluorodeoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478.
29. Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005;63:1053-1059.
30. Westerterp M, Omloo JM, Sloof GW, et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in esophageal cancer by FDG-PET. Int J Hyperthermia. 2006;22:149-160.
31. Wieder HA, Brucher BLDM, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
32. Wieder HA, Beer AJ, Lordick F, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005;46:2029-2034.
33. Westerterp M, Van Westreenen HL, Sloof GW, et al. Role of positron emission tomography in the (re-) staging of aesophageal cancer. Scand J Gastroenterol. 2006;41:116-122.
34. Van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;22:3805-3812.
35. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using 18F-2- fluoro-2-deoxy-D-glucose and positron emission tomography: An overview of different analytical methods. Eur J Nucl Med. 2000;27:731-743.
36. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059-1066.
37. Gillham CM, Lucey JA, Keogan M, et al. 18FDG uptake during induction chemoradiation for esophageal cancer fails to predict histomorphological tumour response. Br J Cancer. 2006;95:1174-1179.
38. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
39. Kroep JR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-18F- fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer: A comparison of different analytical methods. Mol Imaging Biol. 2003;5:337-346.